The purpose of this funding opportunity announcement (FOA) is to invite applications for testing laboratories, research projects, and Phase II SBIR applications to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion, tMCAo).
Awarded investigators will become part of the network and will collaborate with the SPAN Coordinating Center,testing laboratories and other intervention contributors to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke.
If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion.
Separate FOAs are issued to solicit applications for cerebroprotective intervention research projects from small businesses (RFA-NS-22-033), non-small business cerebroprotective intervention research projects
(RFA-NS-22-032), and to become a testing laboratory (RFA-NS-22-003).
RFA Links:
- Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Testing Laboratories (U01 Clinical Trial Not Allowed)
- Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies For Acute Cerebroprotection- Interventions (U01 Clinical Trial Not Allowed)
- Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection- Interventions from Small Businesses (U44 Clinical Trial Not Allowed)